Division of Nephrology, Baylor College of Medicine, Houston, TX, USA.
Am J Clin Nutr. 2010 Apr;91(4):1128S-1132S. doi: 10.3945/ajcn.2010.28608B. Epub 2010 Feb 24.
Muscle wasting increases the morbidity and mortality associated with chronic kidney disease (CKD) and has been attributed to malnutrition. In most patients, this is an incorrect diagnosis because simply feeding more protein aggravates uremia. Instead, there are complex mechanisms that stimulate loss of skeletal muscle, involving activation of mediators that stimulate the ATP-dependent ubiquitin-proteasome system (UPS). Identified mediators of muscle protein breakdown include inflammation, metabolic acidosis, angiotensin II, and neural and hormonal factors that cause defects in insulin/insulin-like growth factor I (IFG-I) intracellular signaling processes. Abnormalities in insulin/IGF-I signaling activate muscle protein degradation in the UPS and caspase-3, a protease that disrupts the complex structure of muscle proteins to provide substrates for the UPS. During the cleavage of muscle proteins, caspase-3 leaves behind a characteristic 14-kD actin fragment in the insoluble fraction of muscle, and characterization of this fragment identifies the presence of muscle catabolism. Thus, it could become a marker of excessive muscle wasting, providing a method for early detection of muscle wasting. Another consequence of activation of caspase-3 in muscle is stimulation of the activity of the proteasome, which increases the degradation of muscle proteins. Treatment strategies for blocking muscle wasting include correction of metabolic acidosis, which can suppress muscle protein losses in patients with CKD who are or are not being treated by dialysis. Correcting acidosis also improves bone metabolism in CKD and hence should be a goal of therapy. Exercise training is a potentially beneficial approach, but more information is needed to optimize exercise regimens. Replacing testosterone deficits can improve muscle mass in men, but dosing and side effects in women have not been adequately tested. Although insulin resistance occurs early in the course of CKD, there are no effective means of correcting it. Consequently, new therapies that can safely suppress muscle wasting are needed.
肌肉减少症会增加与慢性肾脏病(CKD)相关的发病率和死亡率,并且一直归因于营养不良。在大多数患者中,这是一个不正确的诊断,因为简单地增加更多的蛋白质会加重尿毒症。相反,存在刺激骨骼肌丧失的复杂机制,涉及激活刺激 ATP 依赖性泛素蛋白酶体系统(UPS)的介质。肌肉蛋白分解的鉴定介质包括炎症、代谢性酸中毒、血管紧张素 II 和神经和激素因子,这些因子导致胰岛素/胰岛素样生长因子 I (IGF-I) 细胞内信号转导过程的缺陷。肌肉蛋白分解的异常使 UPS 和半胱天冬酶-3 中的肌肉蛋白降解激活,半胱天冬酶-3 是一种蛋白酶,破坏肌肉蛋白的复杂结构,为 UPS 提供底物。在肌肉蛋白的切割过程中,半胱天冬酶-3 在肌肉的不溶性部分中留下特征性的 14kD 肌动蛋白片段,并且该片段的特征鉴定确定了肌肉分解代谢的存在。因此,它可以成为肌肉过度消耗的标志物,为早期检测肌肉消耗提供了一种方法。半胱天冬酶-3 在肌肉中的激活的另一个后果是刺激蛋白酶体的活性,这增加了肌肉蛋白的降解。阻止肌肉消耗的治疗策略包括纠正代谢性酸中毒,这可以抑制正在接受或未接受透析治疗的 CKD 患者的肌肉蛋白损失。纠正酸中毒还改善了 CKD 中的骨代谢,因此应该是治疗的目标。运动训练是一种潜在有益的方法,但需要更多的信息来优化运动方案。替代睾酮缺乏症可以改善男性的肌肉质量,但在女性中,剂量和副作用尚未得到充分测试。尽管胰岛素抵抗在 CKD 早期发生,但没有有效的方法来纠正它。因此,需要安全抑制肌肉消耗的新疗法。